BNP Paribas Financial Markets’s Aimmune Therapeutics AIMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-10,850
Closed -$374K 4276
2020
Q3
$374K Buy
10,850
+1,172
+12% +$25K ﹤0.01% 2389
2020
Q2
$162K Sell
9,678
-17,418
-64% -$296K ﹤0.01% 2578
2020
Q1
$391K Buy
27,096
+20,851
+334% +$533K ﹤0.01% 2483
2019
Q4
$209K Sell
6,245
-1,708
-21% -$47.7K ﹤0.01% 2933
2019
Q3
$167K Buy
7,953
+2,099
+36% +$42.9K ﹤0.01% 2849
2019
Q2
$122K Sell
5,854
-4,203
-42% -$86.5K ﹤0.01% 2915
2019
Q1
$225K Buy
10,057
+9,052
+901% +$213K ﹤0.01% 2627
2018
Q4
$24K Sell
1,005
-1,467
-59% -$38K ﹤0.01% 3038
2018
Q3
$67.4K Buy
2,472
+199
+9% +$5.63K ﹤0.01% 2933
2018
Q2
$61.1K Sell
2,273
-5,220
-70% -$160K ﹤0.01% 3030
2018
Q1
$239K Buy
7,493
+214
+3% +$7.53K ﹤0.01% 2697
2017
Q4
$275K Buy
7,279
+2,881
+66% +$93K ﹤0.01% 2801
2017
Q3
$109K Buy
4,398
+386
+10% +$8.32K ﹤0.01% 2732
2017
Q2
$82.5K Buy
4,012
+3,561
+790% +$67.9K ﹤0.01% 2913
2017
Q1
$9.8K Sell
451
-1,350
-75% -$27.7K ﹤0.01% 3182
2016
Q4
$36.8K Sell
1,801
-371
-17% -$7.58K ﹤0.01% 2963
2016
Q3
$32.6K Buy
2,172
+1,070
+97% +$14.4K ﹤0.01% 2641
2016
Q2
$11.9K Buy
1,102
+1,097
+21,940% +$14.9K ﹤0.01% 2825
2016
Q1
$68 Sell
5
-2,277
-100% -$35.5K ﹤0.01% 2633
2015
Q4
$42.1K Buy
2,282
+217
+11% +$4.01K ﹤0.01% 2929
2015
Q3
$52.3K Buy
+2,065
New +$48.3K ﹤0.01% 2828

BNP Paribas Financial Markets's AIMT Position: Q4 2020 in Review

BNP Paribas Financial Markets sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 10,850 shares — an estimated $374K sold.

BNP Paribas Financial Markets first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $391K in Q1 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • BNP Paribas Financial Markets reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 10,850 Aimmune Therapeutics shares in Q4 2020, an estimated $374K.
  • BNP Paribas Financial Markets first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
  • BNP Paribas Financial Markets's Aimmune Therapeutics position peaked at $391K in Q1 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2020, filed 10 Feb 2021.